MedTrace Logo

Using LUminoMark vs Coventional Practice for Targeted Axillary Surgery

NCT06903429 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2025-03-30

No results posted yet for this study

Summary

The purpose of this study was to compare the use of LuminoMarkTM as a method of targeting axillary lymph nodes with other existing methods used in each institution, such as charcoal staining, needle targeting, and ultrasound-guided skin marking, in patients with breast cancer clinically suspected of metastasis, with or without clipping at the time of diagnosis, regardless of the presence or absence of neoadjuvant chemotherapy. By doing so, the investigators aimed to confirm the safety and usefulness of LuminoMarkTM as a targeting method.

Conditions

Interventions

PROCEDURE

Targeting of axillary lymph nodes using LuminoMark

This group used LuminoMark as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, comparing it to existing methods (charcoal staining, needle targeting, ultrasound-guided skin marking) to assess its safety and effectiveness, with procedural differences based on neoadjuvant chemotherapy status.

PROCEDURE

Targeting of axillary lymph nodes using conventional method

This group used conventional method (charcoal staining, needle targeting, ultrasound-guided skin marking) as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, with procedural differences based on neoadjuvant chemotherapy status.

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Gangnam Severance Hospital

    collaborator OTHER

  • Chung-Ang University Hosptial, Chung-Ang University College of Medicine

    collaborator OTHER

  • Myongji Hospital

    collaborator OTHER

  • Soonchunhyang University Hospital

    collaborator OTHER

  • Kyungpook National University Chilgok Hospital

    lead OTHER

Principal Investigators

  • Korean Breast Cancer Society Study Group · Korean Breast Cancer Society Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-12-31
Completion
2027-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06903429 on ClinicalTrials.gov